Evoq Remedies Ltd
- Market Cap ₹ 7.04 Cr.
- Current Price ₹ 2.83
- High / Low ₹ 6.11 / 2.27
- Stock P/E
- Book Value ₹ 17.8
- Dividend Yield 0.00 %
- ROCE -0.56 %
- ROE -0.54 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.16 times its book value
- Debtor days have improved from 160 to 55.1 days.
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -11.2%
- Promoter holding is low: 0.02%
- Company has a low return on equity of 0.29% over last 3 years.
- Contingent liabilities of Rs.6.55 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 3.25 | 9.07 | 10.02 | 16.78 | 20.39 | 4.05 | 11.76 | 25.51 | |
| 3.23 | 9.07 | 9.07 | 15.32 | 24.12 | 5.69 | 13.99 | 26.96 | |
| Operating Profit | 0.02 | 0.00 | 0.95 | 1.46 | -3.73 | -1.64 | -2.23 | -1.45 |
| OPM % | 0.62% | 0.00% | 9.48% | 8.70% | -18.29% | -40.49% | -18.96% | -5.68% |
| 0.00 | 0.00 | 0.00 | 0.00 | 6.02 | 2.26 | 2.41 | 1.25 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.05 | 0.05 |
| Profit before tax | 0.02 | 0.00 | 0.95 | 1.46 | 2.29 | 0.61 | 0.13 | -0.25 |
| Tax % | 0.00% | 25.26% | 25.34% | 29.26% | 26.23% | 30.77% | -4.00% | |
| 0.01 | 0.00 | 0.72 | 1.09 | 1.62 | 0.45 | 0.09 | -0.24 | |
| EPS in Rs | 10.00 | 0.00 | 720.00 | 0.80 | 1.19 | 0.33 | 0.04 | -0.10 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 8% |
| TTM: | 117% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -367% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -40% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 0% |
| Last Year: | -1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.01 | 13.60 | 13.60 | 13.60 | 24.90 | 24.90 |
| Reserves | 0.01 | 0.01 | 0.73 | 9.57 | 11.19 | 11.64 | 19.64 | 19.40 |
| 0.00 | 0.01 | 0.00 | 8.16 | 9.58 | 4.24 | 0.00 | 0.07 | |
| 2.12 | 5.62 | 7.30 | 2.00 | 0.53 | 7.39 | 5.47 | 7.57 | |
| Total Liabilities | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 | 50.01 | 51.94 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.22 | 0.17 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2.14 | 5.65 | 8.04 | 33.33 | 34.89 | 36.86 | 49.79 | 51.77 | |
| Total Assets | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 | 50.01 | 51.94 |
Cash Flows
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 0.01 | -0.02 | 0.03 | -26.43 | -4.35 | 5.32 | -14.62 | -0.28 | |
| 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 | -0.26 | 0.00 | |
| 0.00 | 0.00 | 0.00 | 29.49 | 1.42 | -5.34 | 14.97 | 0.07 | |
| Net Cash Flow | 0.01 | -0.02 | 0.03 | 3.06 | -2.94 | -0.03 | 0.09 | -0.21 |
| Free Cash Flow | 0.01 | -0.02 | 0.03 | -26.43 | -4.36 | 5.31 | -14.88 | -0.28 |
| CFO/OP | 50% | 3% | -1,785% | 99% | -334% | 654% | 19% |
Ratios
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 138.14 | 189.94 | 249.16 | 552.50 | 308.25 | 156.81 | 267.54 | 55.09 |
| Inventory Days | 3.39 | 2.42 | 6.97 | 20.66 | 38.33 | 732.34 | 61.90 | 23.92 |
| Days Payable | 239.57 | 226.66 | 315.25 | 32.05 | -10.20 | 767.44 | 97.59 | 10.89 |
| Cash Conversion Cycle | -98.04 | -34.30 | -59.11 | 541.11 | 356.78 | 121.72 | 231.85 | 68.12 |
| Working Capital Days | 1.12 | 1.21 | 26.23 | 436.56 | 440.90 | 2,263.00 | 1,369.06 | 631.27 |
| ROCE % | 0.00% | 246.75% | 9.11% | 6.97% | 1.91% | 0.35% | -0.56% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Advance from Customers Rs. Lakhs |
|
||||
| Inventory (Stock-in-Hand) Rs. Lakhs |
|||||
| Purchases of Stock-in-Trade Rs. Lakhs |
|||||
| Sales Commission Income Rs. Lakhs |
|||||
| Trade Receivables Rs. Lakhs |
|||||
| Export Order Secured Rs. Crores |
|||||
Extracted by Screener AI
Documents
Announcements
-
Integrated Filing (Finance) For The Half Year And Year Ended On 31St March, 2026
30 May - Evoq Remedies posts FY26 loss of ₹25.10 lakh; auditor flags going-concern uncertainty, GST ₹655.03 lakh, SEBI probe.
-
Appointment Of M/S. Jay Pandya & Associates (FRN: S2024GJ963300), Company Secretaries, Ahmedabad, As Secretarial Auditor Of The Company For The Financial Year 2025-26.
30 May - FY26 audited results approved on 30 May 2026; auditors issued qualified opinion citing going-concern risk and SEBI investigation.
-
Submission Of Audited Financial Results For The Half Year And Year Ended On 31St March, 2026 Along With Auditor'S Report.
30 May - Board approved FY26 audited results; auditor issued qualified opinion citing going-concern risk, GST demand, SEBI probe.
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Saturday, 30Th May, 2026 And Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
30 May - Board approved audited FY26 results; auditor issued qualified opinion with going-concern uncertainty; Jay Pandya appointed secretarial auditor.
-
Board Meeting Intimation for Intimation For Rescheduling Of Board Meeting From 27Th May, 2026 To 30Th May, 2026
27 May - Board meeting rescheduled to 30 May 2026 to approve audited financial results for year ended 31 March 2026.
Business Overview:[1]
EVOQRL deals in the trading of the pharma
products and commission agent in pharma products, etc.